Zoll, Kranz & Borgess Files Depakote Lawsuit Against Drug Manufacturers on Behalf of Child with Multiple Autism Spectrum Disorders

Zoll, Kranz & Borgess (ZKB) has filed suit against drug manufacturers, Abbott Laboratories and AbbVie, Inc. on behalf of a child with multiple autism spectrum disorders, whose mother was prescribed and took the anti-seizure drug, Depakote, while pregnant.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Toledo, Ohio (PRWEB) January 11, 2014

Zoll, Kranz & Borgess (ZKB) has filed suit on behalf of a child diagnosed with multiple autism spectrum disorders, whose mother was prescribed and took the anti-seizure drug, Depakote, while pregnant.

The complaint alleges that the drug manufacturers, Abbott Laboratories and AbbVie, Inc., knew or should have known of Depakote’s dangers and risks to a fetus when taken by pregnant women, including the risk of cognitive problems (e.g. decreased IQ scores, autism and asperger’s syndrome) and physical birth defects (e.g.spina bifida, atrial septal defect, cleft palate, hypospadias, extra fingers or toes, and craniosynostosis). Yet, despite this knowledge, the complaint alleges that the drug manufacturers failed to adequately warn or instruct women, their physicians or the general public of the nature and extent of the risks to a fetus. Rather the drug manufacturers promoted the drug, including for off-label uses, even though there were other common drugs which were as effective or more effective for treatment of those conditions and which do not involve the severe risks associated with Depakote.

In a safety communication dated 05/06/13, the U.S. Food and Drug Administration (FDA) advised health care professionals and women that Depakote and related products are contraindicated and should not be taken by pregnant women for the prevention of migraine headaches. The FDA also raised the pregnancy category for Depakote and other valproate medicines used to prevent migraine headaches from category “D” (meaning that the potential benefit of the drug in pregnant women may be acceptable despite its potential risks) to “X” (the risk of use in pregnant women clearly outweighs any possible benefit of the drug).

The suit was filed by ZKB in the United States District Court for the Southern District of Illinois on January 10, 2014. The case number is 3:14-cv-00035-JPG-DGW.

ZKB is nationally recognized for its work on defective drug and medical device cases, such the DePuy ASR hip litigation that recently resulted in a proposed $2.4 billion dollar settlement. ZKB is dedicated to compelling companies to produce safer products. Injured clients and partnering attorneys appreciate and rely upon over 70 years of combined experience in mass torts and multidistrict litigation. To learn more about the law firm, attorneys, or the Depakote lawsuit please visit http://www.ZKBlaw.com.


Contact

  • Pamela Borgess
    Zoll, Kranz & Borgess
    +1 (888) 841-9623
    Email
Follow us on: Contact's Google Plus